Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability.
Official registry: https://clinicaltrials.gov/study/NCT07914907 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences · enrollment listed as 100
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are GenAI-Assisted Clinical Decision Support for RABER Assessment and DMARD Selection. The registry lists allocation as na. Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion.
They plan to enroll about 100 people at Beijing. Taking part typically means study visits and measurements plus check-ins.
Prospective Evaluation of Generative AI-Augmented Clinical Decision-Making for Rheumatoid Arthritis Bone Erosion Risk (RABER) Assessment and DMARD Selection in Routine Care
Interventions: GenAI-Assisted Clinical Decision Support for RABER Assessment and DMARD Selection
Primary outcome (registry wording): Percentage of Participants With a Change in Physician-Assessed Rheumatoid Arthritis Bone Erosion Risk Level After GenAI-Assisted Decision Support
Quan Jiang, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.
NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.
NCT03414502 · Official ClinicalTrials.gov record · University of Nebraska
In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites.
NCT04748809 · Official ClinicalTrials.gov record · University of California, San Diego
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary